Innovative Housing Showcase and Pop Up Village Pulls Up Stakes on Washington DC's National Mall

Data-driven precision medicine

What's your reaction?
I Love It
It's OK
I'm Sad
I Hate It

Tempus is a technology company that is making precision medicine a reality by gathering and analyzing clinical and molecular data at scale. The company claims to be on a mission to provide the necessary tools to usher in an era of precision medicine. Tempus was founded in 2015 by Eric Lefkofsky, founder and CEO of Tempus.

Tempus has built the world’s largest library of clinical and molecular data and an operating system to make that information accessible and useful for patients, physicians, and researchers. With the help of artificial intelligence, the company is helping all patients eventually be on their own personalized therapeutic path, enabling longer and healthier lives. With the right data, Tempus can accelerate cancer research then make use of those data to redefine cancer care. By using data to personalise and optimise medical treatment, Tempus is joining the revolution in medical and healthcare industry.

Currently, Tempus is offering several products and services such as Genomic Sequencing, Clinical Data Structuring, Image Recognition, Biological Modeling, and TIME Trial Program. Tempus’s genomic tests analyse DNA, RNA, and proteomic data to understand a patient’s tumour at the molecular level in order to identify treatment options tailored to each and every patient. The company also ingest and organise clinical notes, lab reports, pathology images, and radiology scans to capture phenotypic, therapeutic, and outcomes data to understand the clinical context for each patient case. Then, their platform will analyse thousands of clinical and molecular data points, connecting physicians with up-to-date treatment options and relevant insights for patients based on their unique molecular profile and the Tempus’s advanced analytics and machine-learning algorithms.

Find more about the company on their website:

Leave a Response